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Abstract
Advances in understanding neurobiology and intellectual disabilities have led to clinical trials 
testing new medications. This study assessed parents’ perceptions of the ability of their son or 
daughter with fragile X syndrome (FXS), an inherited form of intellectual disability, to participate 
in the consent process for clinical trials. Four hundred and twenty-two families participated in a 
survey that included six items assessing various aspects of the ability to provide consent. A rank 
ordering of decisional tasks was found. The easiest task was to understand that the medication was 
different from his or her medical treatment; the most difficult was the ability to understand and 
weigh the potential benefits and risks of study participation. Factor analysis suggested that despite 
the range in difficulty, the six items were best summarized by a single decisional ability score. 
Parents of 29% of males reported that their son was not at all capable of participating, but the 
remainder exhibited a range of decisional skills. Factors associated with this variability include 
age, and parents’ willingness to enroll their child in clinical trials. We conclude that many 
individuals with FXS appear to be able to participate at some level in the consent or assent 
process, but will likely need individualized support to maximize effective participation.
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Any study with human subjects must have a robust consent process to ensure that 
participants understand the study and can determine involvement. But investigators studying 
individuals with intellectual and developmental disabilities (IDD) face a special challenge 
(Becker, Roberts, Morrison, & Silver, 2004; Feudtner & Brosco, 2011). They must 
determine whether an individual can make an informed decision and the supports needed to 
maximize participation in decision making. Fulfilling this obligation requires appreciation of 
the human rights context of research (Iacono & Carling-Jenkins, 2012), knowledge of the 
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person’s disability and skills, and evidence-based adaptations to maximize informed 
decision making (Calveley, 2012; Williams & Moore, 2011).
These issues are important in all human studies, but clinical trials testing new treatments 
may warrant additional scrutiny. Clinical trials are necessary to assure safe and effective 
interventions, but their application to IDD evokes complex considerations (Robotham, King, 
Canagasabey, Inchley-Mort, & Hassiotis, 2011; Welie & Berghmans, 2006). For bot reasons 
of science (the need to demonstrate efficacy in the population for whom a treatment is 
intended) and distributive justice (the need to assure that vulnerable individuals have equal 
access to potentially beneficial treatments), the participation of individuals with IDD in 
research is important (Yan & Munir, 2004). But some will get a placebo, the medication 
may have side effects, blood draws may be needed, and assessments are needed to assess 
efficacy and safety. Researchers want to maximize enrollment to ensure a successful study. 
Parents, hoping to help their child or contribute to new knowledge, may encourage their son 
or daughter to participate—even if some study requirements are uncomfortable or 
demanding. These factors suggest that individuals with IDD should be more actively 
involved in the consent or assent process, but little is known about the extent to which they 
can understand the study, what is expected, and potential risks or benefits.
We have initiated a longitudinal study of decisional capacity and informed consent in fragile 
X syndrome (FXS), the most common inherited form of IDD. As a prelude to our direct 
assessment protocol, we report here a brief survey assessing parent perceptions of their son 
or daughter’s ability to participate in the consent process.
Consent and IDD
By definition, individuals with IDD have cognitive impairments limiting ability to make 
informed choices. Historically, individuals with IDD played virtually no role in life 
decisions (Noll & Trent, 2004). Prevailing views gradually changed throughout the last half 
of the 20th century, as disability rights advocates, parents, and ethicists began calling for 
respect of autonomy and empowerment of individuals with IDD, invoking principles such as 
self-advocacy, self-determination, and normalization (Powers, Dinerstein, & Holmes, 2005).
Although the Common Rule requires protections for pregnant women, prisoners, and 
children, individuals with IDD are relegated to a generic “vulnerable populations” status 
needing additional protections. The regulations require legally effective informed consent 
from participants or their legally authorized representative (LAR). But what constitutes 
“legally effective” is left to the jurisdiction in which the research is conducted. Although 
several groups have called for greater specificity and direction in legislation (e.g., National 
Bioethics Advisory Committee, 1998), none have been forthcoming in the U.S.
Parents, LARs, and researchers would benefit from education and data supporting effective 
strategies for enhancing participation in the consent process, but unfortunately, the empirical 
literature is limited (Cleaver, Ouellette-Kuntz, & Sakar, 2010; Goldsmith, Skirton, & Webb, 
2008). Several studies have described challenges in research recruitment (Evenhuis et al., 
2004; Lennox et al., 2005), but no studies have documented decision-making skills in 
individuals with IDD as a group or in specific subgroups. Most authors acknowledge the 
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wide range of ability. Although a robust consent requirement cannot be waived for 
vulnerable individuals assume that many individuals with IDD could participate in the 
consent process at some level (Goldsmith et al., 2008; Veenstra et al., 2010).
Several factors associated with decisional capacity have been identified, the most obvious of 
which is cognitive ability. But cognition consists of multiple processes including attention, 
memory, executive function, strategy use, and metacognitive processing (Bebko & Luhaorg, 
1998). Virtually nothing is known about their relative contribution to decisional capacity. 
Other related factors include the complexity and presentation of information, the 
relationship between study participants and researchers, caregiver participation, and prior 
experiences in decision making (Cea & Fisher, 2003; Fisher, Cea, Davidson, & Fried, 2006; 
Goldsmith et al., 2008).
Fragile X Syndrome (FXS)
FXS, an inherited disorder resulting in cognitive impairment and other functional 
limitations, exemplifies these challenges. Males typically have moderate intellectual 
disability, but impairment can range from mild to severe; females are more mildly affected, 
ranging from normal cognition to moderate impairment (Hall, Burns, Lightbody, & Reiss, 
2008; Loesch, Huggins, & Hagerman, 2004). FXS is highly associated with a range of co-
occurring conditions, such as attention and behavior problems, anxiety, and autism (Bailey, 
Raspa, Olmsted, & Holiday, 2008).
Recent advances in understanding the molecular basis of FXS have led to a new generation 
of targeted medications (Gross, Berry-Kravis, & Bassell, 2012; Wijetunge, Chattarji, Wyllie, 
& Kind, 2013), with increasing interest in their potential for individuals with autism 
spectrum disorders (ASD) (Baudouin et al., 2012). Shared pathways in the biology of 
neurodevelopmental disabilities suggest that treatments targeting these pathways could 
benefit individuals with diverse causes of IDD (Lipton & Sahin, 2013; Millan, 2013). As a 
result, there has been a significant increase in clinical trials testing medications that target 
critical points in neural pathways (Berry-Kravis et al., 2012; Gross et al., 2012; Jacquemont 
et al., 2011).
To maximize participation in consent for these trials, research is needed to characterize 
profiles of decisional capacity in specific groups of individuals with IDD. Studies of FXS 
have shown particular deficits in sustained attention, response inhibition, working memory, 
and other executive functions associated with decisional capacity (Baker et al., 2011; 
Hooper et al., 2008; Ornstein et al., 2008; Sullivan et al., 2007). Reading is a challenge for 
males (Roberts et al., 2005); a national survey reported that although 44% of adult males 
with FXS could read basic picture books or simple stories, only 19% could read books that 
contain new words or concepts (Bailey, Raspa, Holiday, Bishop, & Olmsted, 2009). In 
contrast, 91% of adult females could read basic picture books or simple stories, and 76% 
could read books that contain new words.
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To provide an initial assessment of the extent to which individuals with FXS could 
participate in the consent process, we included a module on decisional capacity in a parent 
survey. The study was designed to answer three questions:
Question 1. How do parents rate the extent to which their son or daughter with FXS is able 
to make a decision about study participation? We assessed parent perceptions of whether 
their son or daughter would understand six specific tasks in the consent process. We 
hypothesized that we would find a range of abilities, but wanted to know the distribution 
across each, determine the proportion that parents consider not capable on any dimensions 
of decisional capacity, and ascertain whether parents considered some fully capable of 
participating in all aspects of consent.
Question 2. Are there identifiable components of decision-making, and are some tasks more 
difficult than others? We conducted exploratory analyses to determine whether the six items 
would result in a single factor, and then tested the assumption that items requiring more 
complex understanding would be significantly more difficult than more concrete tasks.
Question 3. What factors are associated with variability in parent ratings? We hypothesized 
that males and younger individuals with FXS would be rated as having lower decisional 
capacity than females or older individuals with FXS. We also tested whether respondent 
(parent) gender, education, and interest in clinical trial participation were associated with 
ratings of decisional capacity.
METHODS
Participants
The study was part of a national survey of families affected by FXS. Participants were 
recruited from a registry of more than 1000 families of children with FX; announcements 
were also posted on the web sites of the National Fragile X Foundation (www.nfxf.org) and 
FRAXA Research Foundation (www.fraxa.org). A total of 730 families completed the entire 
survey. Of those, 422 had a son or daughter with FXS ≥12 years of age. Although children 
<18 years are not legally able to consent, we were interested in earlier indications of 
decisional capacity and thus included younger children in the study.
One parent completed the survey on behalf of the family. Most respondents were white 
(93%), others were Hispanic (2%), African American (2%), or other races/ethnicities (3%). 
Thirty-eight percent had a 2-year college degree or less education, 34% a 4-year degree, and 
28% a graduate or professional degree. Approximately one-quarter had an annual family 
income of $50,000 or less (24.5%), 36.4% $50,001 – $100,000, and 39% >$100,000. Most 
were mothers (90%), married (81%), and employed (65%). Their mean age was 53.1 years 
(10.3 SD). They had an average of 1.6 children (0.8 SD), and reported on a total of 505 
children with FXS ages 12 and older. Age ranges of the children were 12 – 17 years (31%), 
18 – 22 years (22%), 23 – 29 years (22%), and ≥30 (25%). Most children were males (89%).
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Survey items were reviewed by the Institutional Review Board at the first author’s home 
institution. Because we asked parents provided information about their adult son or 
daughter, the IRB had to consider whether we could ask parents these questions without 
their son or daughter’s consent. The IRB agreed that most males with FXS would be 
considered “decisionally impaired” and thus allowed parent report. However, because 
females are more mildly affected, the IRB determined that we could only ask parents about 
their adult daughter if they were the legal guardian of that child. Given that we had only a 
total of 58 females in the study and the adult females were more severely involved 
individuals who needed a legal guardian, we limit our report on females to a brief summary.
Procedures
Respondents completed the survey online (94%) or by telephone (6%). Parents were given a 
brief study description, assured that it was voluntary and confidential, and asked to read a 
consent form and acknowledge that they agreed to survey participation.
Decisional capacity
Respondents completed items about their son or daughter’s participation in clinical trials and 
their ability to consent. Willingness to have their child participate in future clinical trials was 
also ascertained (1 = definitely, 2 = probably, 3 = not sure, 4 = probably not, and 5 = 
definitely not). Respondents were then presented the following scenario: Assume that 
[CHILD] is asked to be in a research study to see whether a new medication is effective. The 
study will last for 6 weeks. During that time, [he/she] will either get the new medicine or a 
sugar pill. [CHILD] will have blood drawn every week, and every other day [he/she] will be 
asked a set of questions about how [he/she] is feeling. The medicine might improve some 
things and might have some mild side effects, such as sleep problems. If this study was 
explained to [CHILD] in relatively simple terms, please rate the extent to which you think 
[he/she] would be able to do the following. Respondents then rated ability to understand that 
(a) he/she is being asked to participate in a study to find out if a medication works for people 
with FXS; (b) the study medication is different from regular treatment; (c) he/she might get 
the medication or a sugar pill; (d) there are both potential benefits and risks of participating; 
and (e) he/she can choose to participate and to withdraw at any time. Respondents also rated 
ability to make a decision about study participation. Each item was rated on a 4-point scale 
(0 = not at all capable; 1 = capable but with a lot of support; 2 = capable with only minimal 
support; 3 = fully capable). The scenario and items were adapted from the MacArthur 
Competence Assessment Tool for Clinical Research (MacCAT-CR) (Appelbaum & Grisso, 
2001), in collaboration with the scale’s primary author.
Data Analysis
We calculated percentages to provide item-level descriptive data. To account for missing 
data, percentages are based on the number of respondents for each question. To examine 
characteristics associated with variation in decisional abilities, we calculated a total ability-
to-consent score, summing the six items (range 0–18). Items were rank-ordered by 
difficulty, and paired t-test procedures with a Bonferroni correction for multiple 
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comparisons were used to compare adjacent items. We conducted a multiple regression 
analysis using child age, respondent education, respondent gender, and parents’ willingness 
to participate in clinical trials as predictors.
RESULTS
Views about Clinical Trials
Parents generally were positive about clinical trials. When asked if they would be willing for 
their son or daughter to participate in one, a majority responded definitely (28.8%) or 
probably (29.4%). Some were unsure (27.4%), and only a few responded probably not 
(11.9%) or definitely not (2.6%).
Parent Ratings of Decisional Tasks
Parent ratings of males and females by each decisional task are displayed in Table 1. For 
males, ratings of “not at all capable” ranged from 34.2% to 63.3% across items; for females 
these ratings ranged from 10.3% to 24.1%. The group of males was then sub-divided by age 
(<18 years or ≥18 years), displayed in Table 2, to examine differences in abilities before and 
after the typical age of consent. As expected, parents rated lower decisional abilities for sons 
under age 18 than those 18 or over (see Table 2). For males under 18 years, ratings of “not at 
all capable” ranged from 48.9% to 76.7%, whereas for males ≥18 years, ratings of “not at all 
capable” ranged from 29.6% to 57.6%.
When examining all items simultaneously, 29% of males were rated as “not at all capable” 
on all six items, in comparison with only 7% of females. From another perspective, 32% of 
males and 74% of females had no items rated as “not at all capable,” suggesting a wide 
range of ability and the potential for participation with support. However, for males, ratings 
of “fully capable” ranged from only 2.9% to 15.5% across items; for females these ratings 
ranged from 29.3% to 48.3%. Only 2.2% of males were rated as “fully capable” on all six 
items, in comparison with 25.9% of females.
Item Clustering and Difficulty Level
Using a scoring system from 0 (not at all capable) to 3 (fully capable), we calculated means 
and standard deviations for each item, displayed in Table 3 for males, in order from least to 
most difficult. The tasks receiving the highest ratings (reflecting least difficulty) were 
“understands that this medication is different from his/her regular treatment” and “realizes 
that he/she can choose to participate in the study or withdraw at any time.” The tasks 
receiving the lowest ratings (reflecting the greatest difficulty) were “can make a decision 
about study participation” and “understands and weighs the potential benefits and risks of 
participating in the study.” We ran paired t-tests to compare mean scores on each of the 
adjacent pairs of items. The comparisons between all adjacent items were significant after a 
Bonferroni correction except for two pairs of items: (1) “understands being asked to 
participate” and “can choose to participate or withdraw at any time,” and (2) “understands 
that he/she might get the medication and/or he/she might get a sugar pill” and “make a 
decision about study participation,” providing a clear rank order of difficulty.
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We then calculated a total decisional ability score by summing the item ratings, resulting in 
a score ranging from 0 (not at all capable on all six items) to 18 (fully capable on all six 
items). The distribution of total decisional ability scores for males and females is displayed 
in Figure 1. The distributions are both skewed, but in the opposite direction, reflecting the 
expected differences in cognitive ability between males and females. To determine the 
validity of a single score, we first computed item-total correlations (i.e., the correlation 
between the item and the total score with the item removed) and factor loadings based on a 
1-factor exploratory factor analysis. The item-total correlations were all high, ranging from 
0.86 to 0.90, and the factor loadings ranged from 0.90 to 0.93. Cronbach’s alpha for the 
scale was very high, 0.96. Together these findings suggest that the six items are best 
summarized by a single decisional ability score.
Factors Associated with Decisional Ability
To examine the extent to which variability in decisional ability was associated with selected 
child or family characteristics, we conducted a multiple regression analysis using child age, 
respondent education, respondent gender, and willingness to participate in clinical trials as 
predictors of the total decisional ability score (Table 4). Because of the small number of 
females, the regression analysis was restricted to males. Parent willingness to have their 
child participate in a clinical trial and child age were significantly (p<.01) associated with 
decisional ability. Parents interested in clinical trials were more likely to rate their son 
higher in decisional ability. Age was also a significant predictor, as evidenced by the item 
level ratings in Table 2. The mean total score for males under age 18 was 3.47 (SD = 4.2); 
whereas for males ≥18 years the mean was 5.80 (SD = 5.4). The full distribution of total 
scores for males as a function of age is displayed in Figure 2. Although the regression line 
shows a positive association with age, the figure demonstrates the high degree of variability 
both within and across age groups.
DISCUSSION
Translational research in IDD is leading to new treatments targeting core disease 
mechanisms rather than presenting symptoms (Wang et al., 2013). This research has led to a 
rapid increase in clinical trials to test the efficacy of new medications. Ethical imperatives 
suggest that individuals with IDD ought to have a say in whether they will enroll in clinical 
trials, but empirical data on their decisional skills is lacking. Researchers, parents, and IRB 
members need data and assessment tools so that modifications in the consent process can be 
made to support and maximize participation in decision making in either consent or assent to 
participate. Unfortunately the literature is scant, and to the best of our knowledge, there are 
no published reports of decisional abilities in specific groups of individuals with IDD.
This study is an initial attempt to fill this void by assessing parents’ perspectives on the 
decisional abilities in FXS. Because a hallmark feature of FXS is cognitive impairment, 
limitations in decisional ability were expected. However, variability in cognitive 
development and the prevalence of co-occurring conditions (Bailey et al., 2008) suggest that 
a range of functioning is possible. We also wanted to determine if some tasks were more 
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difficult than others. Finally, we wanted to identify characteristics associated with variability 
in decisional skills.
Parents of 29% of males reported that their son was “not at all capable” of participating in 
any of the six decisional tasks included in our survey. But the remaining parents reported 
that their son could participate in at least some of these tasks, although virtually all of them 
would need significant support to do so. The six tasks were not of equal difficulty, and the 
two rated as most challenging—weighing benefits and risks and making a decision about 
study participation—are central to the consent process and indeed reflect the ultimate goal of 
informed consent. As expected, males were substantially less able to participate in the 
consent process than females and adult males had more decisional skills than adolescents.
Parent education was not associated with ratings of decisional ability, but parents who were 
more interested in having their son or daughter participate in a clinical trial rated their 
children as having more decisional skills than parents who were less certain about or 
opposed to clinical trial participation. Although one reason for this finding might be a 
tendency for parents who want their children to participate in research to attribute higher 
levels of decisional abilities to them, the causal arrow could point in the opposite direction. 
Parents who perceive their children as functioning at a higher level, and thus better able to 
participate in decision-making, may be more willing to see them enter clinical trials. We are 
not able to distinguish between these possibilities based on our data, and further exploration 
of this question might help to better illuminate the nature of parental perspectives on 
research participation.
Several limitations must be acknowledged. First, the findings are based on only one parent’s 
report of decisional ability, the validity of which is unknown especially if some carrier 
parents have mild impairments in executive function (Kraan et al., 2013). Some parents may 
never have had to consider their child’s ability to consent and may not have fully grasped 
the tasks described. Alternatively, having cared for and observed their children over many 
years, they probably had a strong sense of abilities and limitations. The usefulness of these 
findings will be enhanced by direct assessments of decisional skills and factors associated 
with decisional capacity, and by further examination of other parent characteristics 
potentially associated with variability in ratings. Second, the findings are primarily limited 
to males, as the female sample was much smaller and the adult females studied are not 
representative of the broader population of adult females with FXS. Finally, the survey 
sample is primarily White and all live in the U.S. Cross-cultural and international contexts 
almost certainly play important roles in shaping both perceptions of disability and policies 
regarding consent and approaches to research (Roberts, Petticrew, Liabo, & Macintyre, 
2012), and further investigation of these issues in other contexts is essential.
BEST PRACTICES
Early research on strategies to enhance participation in consent focused on simplifying 
language and modifying the presentation (Bjorn, Rossel, & Holm, 1999; Dresden & Levitt, 
2001; Murphy, O’Keefe, & Kaufman, 1999). Multimedia formats (slides, videos, touch-
screens) have been tested (Agre et al., 2003; Dunn et al., 2002), as well as test-teach 
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paradigms (Stiles, Poythress, Hall, Falkenbach, & Williams, 2001; Wirshing, Wirshing, 
Marder, Liberman, & Mintz, 1998). But most of these studies have not focused on 
individuals with IDD. Goldsmith, Skirton, and Webb (2008) reviewed studies of 
interventions for individuals with ID and found that life experiences—residence, history of 
decision making, previous health experiences—contributed to the ability to consent (Arscott, 
Dagnan, & Kroese, 1999; Cea & Fisher, 2003; Dye, Hare, & Hendy, 2007; Fisher et al., 
2006). Also, method of presentation is important, especially for individuals with poor 
communication skills or lower memory ability (Dunn et al., 2006; Wong, Clare, Holland, 
Watson, & Gunn, 2000). Many studies show that general intelligence, verbal ability, and 
memory are correlated with ability to consent (Arscott et al., 1999; Cea & Fisher, 2003; Dye 
et al., 2007; Fisher et al., 2006; Wong et al., 2000).
Research Agenda
These findings should be validated using objective assessments, and systematic studies of 
parent perceptions and parent agreement on decisional abilities are needed. Factors 
associated with the capacity to consent, such as executive functions, need to be assessed 
(Mandarelli, Parmigiani, Tarsitani, et al., 2013). We still do not have a validated approach to 
enhance decisional capacity in individuals with IDD (Cleaver et al., 2010). A variety of 
techniques may be needed depending on the participant’s skills (Swaine et al., 2011). New 
technologies, primarily applications designed for tablets such as the iPad, have great 
potential for enhancing communication with people with IDD (Kagohara et al., 2013; 
Palmer, Wehmeyer, Davies, & Stock, 2012; Shane et al., 2012).
Educational Implications
Our findings suggest that most males with FXS will have significant challenges participating 
in the consent process. However, given the variability in decisional abilities, researchers 
should develop strategies to maximize participation and assent or consent. It is likely than no 
single approach will work for all individuals with IDD, necessitating individualized 
assessments, evidence-based supports, and a model that maximizes the goodness-of-fit 
between an individual’s abilities and the consent process (Calveley, 2012; Fisher, 2003).
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Total decisional ability score for males and females with FXS
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Parent ratings of decisional capacity in males with fragile X syndrome as a function of age 
of child.
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Table 1








Understand being asked to participate in study
  Not at all capable 38.1 13.8
  Capable but with a lot of support 37.0 19.0
  Capable with only minimal support 15.0 19.0
  Fully capable 9.9 48.3
Understand that study medication differs from regular
  Not at all capable 34.2 10.3
  Capable but with a lot of support 32.4 20.7
  Capable with only minimal support 17.8 20.7
  Fully capable 15.5 48.3
Understand might get medication or sugar pill
  Not at all capable 51.9 15.5
  Capable but with a lot of support 26.0 17.2
  Capable with only minimal support 13.8 19.0
  Fully capable 8.3 48.3
Understand and weigh potential benefits and risks
  Not at all capable 63.3 24.1
  Capable but with a lot of support 25.0 15.5
  Capable with only minimal support 8.8 31.0
  Fully capable 2.9 29.3
Realize choice and ability to withdraw at any time
  Not at all capable 42.4 17.2
  Capable but with a lot of support 29.6 12.1
  Capable with only minimal support 15.8 22.4
  Fully capable 12.2 48.3
  Able to make a decision about study participation
  Not at all capable 51.0 22.4
  Capable but with a lot of support 31.2 13.8
  Capable with only minimal support 9.9 24.1
  Fully capable 7.9 39.7
Note: Percentages may not sum to 100 due to rounding.
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Table 2






Males 18 or over
(n = 313)
Understand being asked to participate in study
  Not at all capable 48.9 33.6
  Capable but with a lot of support 34.6 38.0
  Capable with only minimal support 12.0 16.3
  Fully capable 4.5 12.1
Understand that study medication differs from regular
  Not at all capable 45.1 29.6
  Capable but with a lot of support 33.1 32.2
  Capable with only minimal support 12.0 20.3
  Fully capable 9.8 18.0
Understand might get medication or sugar pill
  Not at all capable 64.7 46.5
  Capable but with a lot of support 24.8 26.5
  Capable with only minimal support 7.5 16.5
  Fully capable 3.0 10.7
Understand and weigh potential benefits and risks
  Not at all capable 76.7 57.6
  Capable but with a lot of support 18.1 28.0
  Capable with only minimal support 3.8 10.9
  Fully capable 1.5 3.5
Realize choice and ability to withdraw at any time
  Not at all capable 56.1 36.7
  Capable but with a lot of support 28.0 30.2
  Capable with only minimal support 11.4 17.7
  Fully capable 4.6 15.4
  Able to make a decision about study participation
  Not at all capable 66.2 44.6
  Capable but with a lot of support 27.1 33.0
  Capable with only minimal support 2.3 13.1
  Fully capable 4.5 9.3
Note: Percentages may not sum to 100 due to rounding.
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Table 3
Mean ratings and order of difficulty for decisional tasks for males with fragile X syndrome (in increasing 
order of difficulty).
Rank Item Description Mean (SD)
1 Understand that this medication is different from his/her regular treatment 1.26 (1.10)
2 (tied) Realize that he/she can choose to participate in the study or withdraw at any time 1.10 (1.10)
2 (tied) Understand that he/she is being asked to participate in a research study to find out if the medication works for people 
with FXS.
1.09 (1.04)
3 (tied) Understand that he/she might get the medication or he/she might get a sugar pill 0.93 (1.07)
3 (tied) Make a decision about study participation 0.87 (1.02)
4 Understand and weigh the potential benefits and risks of participating in the study 0.65 (0.90)
Note: All pairwise comparisons are significant at p < .05 with Bonferroni correction for multiple comparisons except for the two pairs of items that 
were essentially identical in rank.






















Bailey et al. Page 19
Table 4
Regression model predicting total decisional ability score for Males as a function of willingness to participate 
in a clinical trial; respondent education; and child age





Willingness to have child participate in clinical trial <0.01
  Definitely 2.99 (−0.30–6.28) 0.08
  Probably 1.87 (−1.37–5.11) 0.26
  Not sure .85 (−2.37–4.07) 0.60
  Probably not .84 (−2.57–4.25) 0.63
  Definitely not REF .
Respondent education 0.39
  Some college or less −0.85 (−2.14–0.43) 0.19
  Two or four-year college degree −0.68 (−1.86–0.51) 0.26
  Graduate or professional degree REF .
Respondent gender 0.34
  Male .72 (−.76–2.20) 0.34
  Female REF
Age of child 0.01
  Age 12–17 −3.44 (−4.72–2.15) <0.01
  Age 18–22 −2.32 (−3.72–0.91) <0.01
  Age 23–29 −1.38 (−2.76–0.01) 0.01
  Age 30 and over REF .
Note: REF = reference category
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